Atopic dermatitis
AD · Immunology · 7 drugs · 5 indications
Chronic inflammatory skin condition (eczema).
Competitive Landscape (7 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Donzakimig | UCB | IL-13/IL-22 inhibitor | Multi-specific antibody | SC | PHASE2 |
| Galvokimig | UCB | IL-13/IL-17A/IL-17F inhibitor | Multi-specific antibody | SC | PHASE2 |
| Bimzelx | UCB | IL-17A/F inhibitor | Antibody | SC | APPROVED |
| Olumiant | LLY | JAK inhibitor | Small molecule | ORAL | APPROVED |
| Rinvoq | ABBV | JAK inhibitor | Small molecule | ORAL | APPROVED |
| Dupixent | REGN | IL-4Rα inhibitor (monoclonal antibody) | Monoclonal antibody | SC | APPROVED |
| Moizerto | 4578 | PDE4 inhibitor (oral) | Small molecule | TOPICAL | APPROVED |
Indications (5)
Moderate-to-severe atopic dermatitis (adults & adolescents)
Moderate-to-severe atopic dermatitis
Moderate-severe atopic dermatitis
Pediatric atopic dermatitis
Upcoming Catalysts
Donzakimig - Atopic Dermatitis - Ph2a - ResultsCLINICAL
UCBH2 2025
Rinvoq - Vitiligo - FDA ApprovalREGULATORY
ABBV2026
Rinvoq - GCA - FDA ApprovalREGULATORY
ABBV2026
Rinvoq - Alopecia Areata - Ph3 - Data (UP-AA)CLINICAL
ABBV2026
Rinvoq - HS - Ph3 - DataCLINICAL
ABBV2026
Rinvoq - SLE - Ph3 - DataCLINICAL
ABBV2026
Galvokimig - Atopic Dermatitis - Ph2b - Start/UpdatesCLINICAL
UCB2026
Dupixent - CSU - Ph3 Topline (LIBERTY-CSU CUPID)CLINICAL
REGN2026
Bimzelx - Commercial Momentum UpdatesCOMMERCIAL
UCB2026
Bimzelx vs Risankizumab - PsA - Head-to-Head DataCLINICAL
UCBH2 2026
Data from Supabase · Updated 2026-03-24